Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database

Shuji Uno, Rei Goto, Kenshi Suzuki, Kosuke Iwasaki, Tomomi Takeshima, Tomoko Ohtsu

Research output: Contribution to journalArticle

Abstract

Aims: Various drugs have recently been launched for the treatment of multiple myeloma (MM). This increase in the number of treatment options has potentially changed treatment patterns and medical costs for patients with MM. Japanese public health insurance claims were analyzed to examine the change in the treatment patterns of MM drugs and medical costs per patient. Materials and methods: A claims database provided by Medical Data Vision was used, which includes data from ∼20 million patients from >300 acute care hospitals across Japan. The type of MM drugs prescribed and medical costs for patients with MM between April 2008 and December 2016 were examined using monthly cross-sectional analyses. Patients with an International Classification of Diseases, 10th Revision (ICD-10) diagnosis code of C90.0 were classified as having MM. MM drugs were defined by generic names. Results: In total, 19,137 patients with MM (average age at first diagnosis: 69.6 years; percentage of women: 47.9%) were identified from the database. The percentage of patients prescribed each MM drug changed substantially as novel drugs were launched. Total medical costs increased until 2010, then stabilized. MM drug costs increased from approximately 2010, but costs for other care decreased, particularly for hospitalization (including surgery). Limitations: The database contained data from large, acute care hospitals, which may have caused bias in terms of patients’ clinical history and disease severity. Conclusions: Total medical costs for MM have remained stable since 2010. MM drug costs increased, but costs for other care decreased after the launch of lenalidomide in 2010 and other drugs in 2015 and later. More detailed research is required to confirm whether the launch of novel drugs caused the changes in medical costs.

Original languageEnglish
JournalJournal of Medical Economics
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Health Insurance
Multiple Myeloma
Japan
Cross-Sectional Studies
Databases
Costs and Cost Analysis
Drug Costs
Pharmaceutical Preparations
Therapeutics
International Classification of Diseases
Names
Hospitalization
Public Health

Keywords

  • Cross-sectional analysis
  • drug prescriptions
  • healthcare administrative claims
  • healthcare cost
  • Japan
  • multiple myeloma
  • plasma cell neoplasms
  • real-world data
  • treatment cost

ASJC Scopus subject areas

  • Health Policy

Cite this

Current treatment patterns and medical costs for multiple myeloma in Japan : a cross-sectional analysis of a health insurance claims database. / Uno, Shuji; Goto, Rei; Suzuki, Kenshi; Iwasaki, Kosuke; Takeshima, Tomomi; Ohtsu, Tomoko.

In: Journal of Medical Economics, 01.01.2019.

Research output: Contribution to journalArticle

@article{cb820746ce32428abf1c6e5de887cfc0,
title = "Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database",
abstract = "Aims: Various drugs have recently been launched for the treatment of multiple myeloma (MM). This increase in the number of treatment options has potentially changed treatment patterns and medical costs for patients with MM. Japanese public health insurance claims were analyzed to examine the change in the treatment patterns of MM drugs and medical costs per patient. Materials and methods: A claims database provided by Medical Data Vision was used, which includes data from ∼20 million patients from >300 acute care hospitals across Japan. The type of MM drugs prescribed and medical costs for patients with MM between April 2008 and December 2016 were examined using monthly cross-sectional analyses. Patients with an International Classification of Diseases, 10th Revision (ICD-10) diagnosis code of C90.0 were classified as having MM. MM drugs were defined by generic names. Results: In total, 19,137 patients with MM (average age at first diagnosis: 69.6 years; percentage of women: 47.9{\%}) were identified from the database. The percentage of patients prescribed each MM drug changed substantially as novel drugs were launched. Total medical costs increased until 2010, then stabilized. MM drug costs increased from approximately 2010, but costs for other care decreased, particularly for hospitalization (including surgery). Limitations: The database contained data from large, acute care hospitals, which may have caused bias in terms of patients’ clinical history and disease severity. Conclusions: Total medical costs for MM have remained stable since 2010. MM drug costs increased, but costs for other care decreased after the launch of lenalidomide in 2010 and other drugs in 2015 and later. More detailed research is required to confirm whether the launch of novel drugs caused the changes in medical costs.",
keywords = "Cross-sectional analysis, drug prescriptions, healthcare administrative claims, healthcare cost, Japan, multiple myeloma, plasma cell neoplasms, real-world data, treatment cost",
author = "Shuji Uno and Rei Goto and Kenshi Suzuki and Kosuke Iwasaki and Tomomi Takeshima and Tomoko Ohtsu",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/13696998.2019.1686870",
language = "English",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Current treatment patterns and medical costs for multiple myeloma in Japan

T2 - a cross-sectional analysis of a health insurance claims database

AU - Uno, Shuji

AU - Goto, Rei

AU - Suzuki, Kenshi

AU - Iwasaki, Kosuke

AU - Takeshima, Tomomi

AU - Ohtsu, Tomoko

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aims: Various drugs have recently been launched for the treatment of multiple myeloma (MM). This increase in the number of treatment options has potentially changed treatment patterns and medical costs for patients with MM. Japanese public health insurance claims were analyzed to examine the change in the treatment patterns of MM drugs and medical costs per patient. Materials and methods: A claims database provided by Medical Data Vision was used, which includes data from ∼20 million patients from >300 acute care hospitals across Japan. The type of MM drugs prescribed and medical costs for patients with MM between April 2008 and December 2016 were examined using monthly cross-sectional analyses. Patients with an International Classification of Diseases, 10th Revision (ICD-10) diagnosis code of C90.0 were classified as having MM. MM drugs were defined by generic names. Results: In total, 19,137 patients with MM (average age at first diagnosis: 69.6 years; percentage of women: 47.9%) were identified from the database. The percentage of patients prescribed each MM drug changed substantially as novel drugs were launched. Total medical costs increased until 2010, then stabilized. MM drug costs increased from approximately 2010, but costs for other care decreased, particularly for hospitalization (including surgery). Limitations: The database contained data from large, acute care hospitals, which may have caused bias in terms of patients’ clinical history and disease severity. Conclusions: Total medical costs for MM have remained stable since 2010. MM drug costs increased, but costs for other care decreased after the launch of lenalidomide in 2010 and other drugs in 2015 and later. More detailed research is required to confirm whether the launch of novel drugs caused the changes in medical costs.

AB - Aims: Various drugs have recently been launched for the treatment of multiple myeloma (MM). This increase in the number of treatment options has potentially changed treatment patterns and medical costs for patients with MM. Japanese public health insurance claims were analyzed to examine the change in the treatment patterns of MM drugs and medical costs per patient. Materials and methods: A claims database provided by Medical Data Vision was used, which includes data from ∼20 million patients from >300 acute care hospitals across Japan. The type of MM drugs prescribed and medical costs for patients with MM between April 2008 and December 2016 were examined using monthly cross-sectional analyses. Patients with an International Classification of Diseases, 10th Revision (ICD-10) diagnosis code of C90.0 were classified as having MM. MM drugs were defined by generic names. Results: In total, 19,137 patients with MM (average age at first diagnosis: 69.6 years; percentage of women: 47.9%) were identified from the database. The percentage of patients prescribed each MM drug changed substantially as novel drugs were launched. Total medical costs increased until 2010, then stabilized. MM drug costs increased from approximately 2010, but costs for other care decreased, particularly for hospitalization (including surgery). Limitations: The database contained data from large, acute care hospitals, which may have caused bias in terms of patients’ clinical history and disease severity. Conclusions: Total medical costs for MM have remained stable since 2010. MM drug costs increased, but costs for other care decreased after the launch of lenalidomide in 2010 and other drugs in 2015 and later. More detailed research is required to confirm whether the launch of novel drugs caused the changes in medical costs.

KW - Cross-sectional analysis

KW - drug prescriptions

KW - healthcare administrative claims

KW - healthcare cost

KW - Japan

KW - multiple myeloma

KW - plasma cell neoplasms

KW - real-world data

KW - treatment cost

UR - http://www.scopus.com/inward/record.url?scp=85075162508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075162508&partnerID=8YFLogxK

U2 - 10.1080/13696998.2019.1686870

DO - 10.1080/13696998.2019.1686870

M3 - Article

C2 - 31682533

AN - SCOPUS:85075162508

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

ER -